Having trouble viewing this email? View in your browser.
ESCMID Logo

8 January 2019
WEEKLY NEWS

Dear colleagues,

Please find below the latest edition of ESCMID Weekly News.

With kind regards,

ESCMID Executive Office.

 

EITaF News: Emergence of deadly Marburg virus in West African fruit bats

EITaF has relayed reports of Marburg virus in fruit bats in Sierra Leone – the first time the infection has been detected in West Africa. IDSA News reported that there have been no reported cases of people sick with Marburg in Sierra Leone, but the virus’s presence in bats means people nearby could be at risk for contracting Marburg virus. Marburg virus is a cousin to Ebola virus that causes a similar, often fatal disease in people.You can read more about this and other breaking news about emerging infections around the world on the EITaF Outbreak News webpage.

› Read more
OPEN CALLS | APPLICATIONS

Registration for ECCMID 2019 - Early Bird fee until
24 January 2019

ECCMID is approaching soon!

To benefit from the early-bird registration deadline, please register before 24 January 2019. Make sure you use our official website to book your hotels to get the best rates.

› Read more

CMI highlight: results from a retrospective cohort study comparing fidaxomicin and oral vancomycin for severe Clostridium difficile infection

Gentry et al compared the clinical outcomes of treatment with fidaxomicin versus oral vancomycin in the management of severe Clostridium difficile infection (CDI). Propensity score matching resulted in two well-matched cohorts consisting of 213 fidaxomicin and 639 oral vancomycin courses. No statistically-significant difference was found for the primary outcome of combined clinical failure or recurrence (68/213, 31.9% vs. 163/639, 25.5%, respectively, P = 0.071). Additionally, no statistically significant differences were found for the secondary outcomes of 30-day (23/213, 10.8% vs 75/639, 11.7%, respectively, P = 0.71), 90-day (48/213, 22.5% vs 140/639, 21.9%, respectively, P = 0.85), and 180-day mortality (62/213, 29.1% vs 186/639, 29.1%, respectively, P = 1.0) between the two treatment groups. Together these results indicate that courses of fidaxomicin or oral vancomycin for severe CDI resulted in similar treatment outcomes. These findings are consistent with current treatment guideline recommendations regarding the use of either agent in the management of severe CDI.

› Read more
 

ESGAP-SWAB Technical Workshop on measuring quantity and quality of antimicrobial use

"If you do not measure, you cannot improve it" (Lord Kelvin) is a paradigm that is especially true for Antimicrobial Stewardship Programs. International Guidelines consider it very important to make use of the large amount of data that we -willingly or unwillingly- collect in everyday practice. The main goal of this ESGAP/SWAB course is to provide participants with practical tools to measure, interpret and present data on the quantity and quality of antimicrobial use in their facilities. Experts in the field) will guide them through this process.

› Read more
ESCMID Executive Office
P.O. Box 214
4010 Basel
Switzerland
Phone +41 61 5080 173
info@escmid.org
www.escmid.org
Follow ESCMID
Visit us on LinkedIn Visit us on YouTube
 
The ESCMID Newsletter is issued on behalf of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) by the ESCMID Executive Office. It contains announcements of ESCMID-related matters and other information of interest to professionals in the infection field.

Tip: To ensure that you receive the ESCMID newsletter in your inbox, add newsletter@escmid.org to your email program’s address book.

You have received this email as a contact of ESCMID or one of its affiliated societies. You can unsubscribe or change your newsletter subscriptions here.